​

Cartesian Therapeutics (RNAC) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Cartesian Therapeutics Revenue Highlights

Latest Revenue (Y)

$38.91M

Latest Revenue (Q)

$452.00K

Main Segment (Y)

Reporting Segments

Cartesian Therapeutics Revenue by Period

Cartesian Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$38.91M49.64%
2023-12-31$26.00M-76.53%
2022-12-31$110.78M30.21%
2021-12-31$85.08M412.60%
2020-12-31$16.60M148.57%
2019-12-31$6.68M639.42%
2018-12-31$903.00K336.23%
2017-12-31$207.00K-97.44%
2016-12-31$8.08M34.47%
2015-12-31$6.01M97.73%
2014-12-31$3.04M-

Cartesian Therapeutics generated $38.91M in revenue during NA 2024, up 49.64% compared to the previous quarter, and up 582.79% compared to the same period a year ago.

Cartesian Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30$452.00K51.68%
2025-06-30$298.00K-72.91%
2025-03-31$1.10M-244.93%
2024-12-31$-759.00K-296.12%
2024-09-30$387.00K-98.84%
2024-06-30$33.45M472.69%
2024-03-31$5.84M-29.35%
2023-12-31$8.27M26.18%
2023-09-30$6.55M24.80%
2023-06-30$5.25M-11.60%
2023-03-31$5.94M-64.64%
2022-12-31$16.80M-18.90%
2022-09-30$20.71M-47.27%
2022-06-30$39.27M15.51%
2022-03-31$34.00M13.57%
2021-12-31$29.94M22.56%
2021-09-30$24.43M24.23%
2021-06-30$19.66M77.95%
2021-03-31$11.05M-7.54%
2020-12-31$11.95M157.23%
2020-09-30$4.65M100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$6.65M100.00%
2019-09-30--100.00%
2019-06-30$13.00K30.00%
2019-03-31$10.00K-98.89%
2018-12-31$903.00K100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--100.00%
2017-12-31$17.00K-37.04%
2017-09-30$27.00K-

Cartesian Therapeutics generated $452.00K in revenue during Q3 2025, up 51.68% compared to the previous quarter, and up 1.35% compared to the same period a year ago.

Cartesian Therapeutics Revenue Breakdown

Cartesian Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reporting Segments$38.91M

Cartesian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reporting Segments (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25
Operating Segment$298.00K$1.10M

Cartesian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Operating Segment (100.00%).

Cartesian Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
FENCFennec Pharmaceuticals$47.54M$9.65M
RNACCartesian Therapeutics$38.91M$452.00K
GNFTGenfit$28.57M$17.08M
MDWDMediWound$18.69M$4.96M
IVAInventiva$17.48M$2.73M
OBIOOrchestra BioMed$2.64M$861.00K
AVTXAvalo Therapeutics$441.00K-
NTHINEONC TECHNOLOGIES$83.00K-
AARDAardvark Therapeutics--
EPRXEupraxia Pharmaceuticals--
NAUTNautilus Bio-$6.52M

RNAC Revenue FAQ

What is Cartesian Therapeutics’s yearly revenue?

Cartesian Therapeutics's yearly revenue for 2024 was $38.91M, representing an increase of 49.64% compared to 2023. The company's yearly revenue for 2023 was $26M, representing a decrease of -76.53% compared to 2022. RNAC's yearly revenue for 2022 was $110.78M, representing an increase of 30.21% compared to 2021.

What is Cartesian Therapeutics’s quarterly revenue?

Cartesian Therapeutics's quarterly revenue for Q3 2025 was $452K, a 51.68% increase from the previous quarter (Q2 2025), and a 16.80% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $298K, a -72.91% decrease from the previous quarter (Q1 2025), and a -99.11% decrease year-over-year (Q2 2024). RNAC's quarterly revenue for Q1 2025 was $1.1M, a -244.93% decrease from the previous quarter (Q4 2024), and a -81.16% decrease year-over-year (Q1 2024).

What is Cartesian Therapeutics’s revenue growth rate?

Cartesian Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -64.87%, and for the last 5 years (2020-2024) was 134.46%.

What are Cartesian Therapeutics’s revenue streams?

Cartesian Therapeutics's revenue streams in c 24 are Reporting Segments

What is Cartesian Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Cartesian Therapeutics was Reporting Segments. This segment made a revenue of $38.91M, representing 100.00% of the company's total revenue.